Biochemical Engineering Special Interest Group
biological engineering professionals
05 October 2016

UK cancer charity and investment firm launch neoantigen biotech

Cancer Research UK and London investment firm Syncona have joined forces to fund and launch a new neoantigen-focused lung cancer biotech. The company, known as Achilles Therapeutics, launched today with £13.2 million, led by Syncona and CRUK’s commercial arm Cancer Research Technology, as well as funding from University College London. Its focus initially is on certain forms of lung cancer, specifically on targets for truncal tumor neoantigen, which are created by specific mutations in a patient’s tumor. Source: Fierce Biotech 5/10/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).